Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KIF20B | Q96Q89 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957213 | 1.00 | PTGES (0.37) | PTGESDYRK1APLAUKIF20BALDH1A1 | |
| SCHEMBL22234251 | 0.81 | BACE1 (0.39) | PTGESDYRK1APLAUKIF20BALDH1A1 | |
| SCHEMBL30316963 | 0.81 | ALDH1A1 (0.43) | PTGESDYRK1APLAUALDH1A1HTT | |
| SCHEMBL24252457 | 0.77 | DYRK1A (0.36) | DYRK1APLAUHTTKMT2APTPN7 | |
| SCHEMBL30451907 | 0.77 | DYRK1A (0.36) | DYRK1APLAUHTTKMT2APTPN7 | |
| SCHEMBL12629416 | 0.77 | CCR1 (0.45) | KIF20BALDH1A1HTTNPSR1KMT2A | |
| SCHEMBL2725327 | 0.73 | DYRK1A (0.36) | PTGESDYRK1APLAUALDH1A1HTT | |
| SCHEMBL1932691 | 0.73 | HTT (0.36) | PTGESDYRK1APLAUALDH1A1HTT | |
| SCHEMBL20374535 | 0.72 | DYRK1A (0.47) | DYRK1APLAUALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30359528 | 0.72 | DYRK1A (0.47) | DYRK1APLAUALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612155-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12150937-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024097559-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3911417-B1 | HETEROCYCLIC NLRP3 MODULATORS , FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-113301962-A | Heterocyclic NLRP3 modulators for the treatment of cancer | 先天肿瘤免疫公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020150114-A1 | HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | PTGES 396/4885DYRK1A 4867/4885PLAU 4436/4885 |
| US-12150937-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | PTGES 396/4885DYRK1A 4867/4885PLAU 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.